Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Developmental Immunotherapy and Tumor Immunobiology

Type: Poster Session

Time: Saturday June 1, 8:00 AM to 11:00 AM

Location: Hall A

Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.

Immune Checkpoint Inhibitors

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Abstract No:

Poster Board Number:
Poster Session (Board #210)

J Clin Oncol 37, 2019 (suppl; abstr 2566)

Author(s): Wendy S. Rubinstein, Li Chen, George Anthony Komatsoulis, Edward Stepanski, Monika Jun, Jizu Zhi, Denise Lau, Jeremy Roberts, Robert S. Miller, Mark S. Walker, Ryan Fukushima, Brigham Hyde, Sean Khozin; American Society of Clinical Oncology’s (ASCO) CancerLinQ, Alexandria, VA; Concerto HealthAI, Boston, MA; Precision Health AI, New York, NY; U.S. Food and Drug Administration, Silver Spring, MD; Tempus, Chicago, IL; ASCO's CancerLinQ, Alexandria, VA; ACORN Research LLC, Memphis, TN

Abstract Disclosures


Background: ICI’s have demonstrated significant clinical benefit since the first FDA approval in 2011 of ipilimumab for metastatic melanoma. Five additional ICI therapies have since been approved across several indications. The objectives of this study were to describe the clinical and demographic features of patients receiving ICI treatment along with utilization patterns in real-world settings. Methods: We conducted a retrospective, observational cohort study using statistically de-identified data from January 2011 to November 2018 in CancerLinQ, ASCO’s real-world oncology database, which now contains EHR data from 49 diverse oncology practices in the U.S. Adult patients diagnosed with any cancer type who received ≥1 dose of an ICI (see Table) and had ≥2 clinical visits were eligible for inclusion. Patients were excluded if they received an ICI prior to its first FDA approval date to avoid inclusion of clinical trial patients. Descriptive statistics were used to examine treatment patterns and clinical characteristics of patients receiving ICIs. Results: This analysis included 12,712 patients who received an ICI. Median patient age was 67.4 years [IQR 59.3, 75.3]; 58% were male. White race made up the highest percent (83%) of ICI patients, followed by Black race (9%) and Other (8%). The most common primary cancers at the start of treatment were lung cancer (36%), melanoma (8%), urothelial cancer (2%) and renal cell carcinoma (2%). Of the 8,444 patients with known disease stage, 5,446 (64%) had Stage IV cancer. Breakdown of ICI treatment patterns can be found in the accompanying table. Uptake of ICIs was the most rapid for nivolumab, which had the highest use (49%), followed by pembrolizumab for rapid adoption and use (30%). Conclusions: This analysis gives insights into patient characteristics and real-world treatment patterns for ICIs. ICIs were used most widely in males, lung cancer patients and patients with advanced disease. These baseline characteristics inform our analyses of ICI use in patients with autoimmune disease, also reported herein.

ICI MedicationN (%)
Atezolizumab644 (5)
Avelumab22 (0)
Combination ICI619 (5)
Durvalumab116 (1)
Ipilimumab1303 (10)
Nivolumab6219 (49)
Pembrolizumab3789 (30)

Other Abstracts in this Sub-Category:


1. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 101 First Author: Toni K. Choueiri
Category: Developmental Immunotherapy and Tumor Immunobiology - Immune Checkpoint Inhibitors


2. Phase I study of pembrolizumab in people with HIV and cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 2500 First Author: Thomas S. Uldrick
Category: Developmental Immunotherapy and Tumor Immunobiology - Immune Checkpoint Inhibitors


3. Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.

Meeting: 2019 ASCO Annual Meeting Abstract No: 2501 First Author: María González-Cao
Category: Developmental Immunotherapy and Tumor Immunobiology - Immune Checkpoint Inhibitors